内分泌学分野の英文校正サンプル

エナゴは、内分泌系と関連する疾病などに関する論文を多数校正し、高い評価をいただいてきました。糖尿病治療、肥満診療、下垂体障害など、扱う内容が多岐にわたる内分泌学分野において、専門知識を有する校正者が校閲・校正を行います。こちらが内分泌学論文の修正履歴付き校正サンプルです。アドバンス英文校正とノーマル英文校正の2つのサービスプランを比較いただき、各種サンプルをPDF形式でダウンロードすることもできます。

The term β-thalassemia intermedia (β-TITI) is a term that describes patients witha form of milder anemia than patients with β-thalassemia major. Ineffective erythropoiesis, chronic hemolytic anemia, and iron overload are the main factors responsible for prognosis the disease process in patients with β-TI. Chronic hemolytic anemia may have such adverse effects asresult in increased in gastrointestinal iron absorption and iron overload, which in turn can cause endocrine abnormalities, diabetes mellitus, osteoporosis, hypothyroidism, and hypogonadism. The options available for managing patients with β-TI include Iron iron chelation therapy, splenectomy, transfusion therapy, and modulation of fetal hemoglobin (HbF) production are several available options for managing patients with β-TI. Pharmacological agents that increase γ-globin production [e.g., like Hydroxyurea hydroxyurea (HU), )], as evidenced by an increased in HbF levels, have been considered as therapeutic agents for patients with β-thalassemiaTI. Increaseding the synthesis of fetal hemoglobinHbF 1 synthesis can help reduce anemia and, thereby, improve improving the clinical condition of these patients of patients with β-TI. In several patients with β-TI and in patients with sickle-cell disease, a riseIncreases in total HbF levels during HU treatment has have been repeatedly reported during HU treatment in several patients with β-TI and in those with sickle-cell disease. HU treatment can reduce blood transfusion dependency and even make some patients transfusion free, increasing their energy state level and decreasing splenomegaly. HU treatmentIt 2 also is protectiveprotects for against hypothyroidism, pulmonary hypertension, extramedullary hematopoiesis, leg ulcers, and osteoporosis. The commonest most common side effects of HU therapy treatment 3 include neutropenia and thrombocytopenia, ; both of which these are predictable and can be easily manageablemanaged. In the few studies conducted on the side effects of HU treatment in β-TI patients with β-TI, dermatological, neurological, and gastrointestinal adverse effects were have been seen observed without any reports of endocrine abnormality, bone marrow suppression, or hematological toxicity. In the present study,We aimed to perform medium- to long-term follow-up of chronic low-dose HU 4 treatment was inspected to for analyze analyzing the its effect of HU treatment on the thyroid function of patients with β-TI.

Explanations

β-thalassemia intermedia (β-TI) is a term that describes is patients witha milder form of anemia than patients with β-thalassemia major. Ineffective erythropoiesis, chronic hemolytic anemia, and iron overload are the main factors responsible for the disease process prognosis in patients with β-TI. Chronic anemia may have such adverse effects, such as increased in gastrointestinal iron absorption and iron overload, which canin turn can cause endocrine abnormalities, diabetes mellitus, osteoporosis, hypothyroidism, and hypogonadism. Iron chelation therapy, splenectomy, transfusion therapy, and modulation of fetal hemoglobin (HbF) production are several availablethe options available for managing patients with β-TI. Pharmacological agents that increase γ-globin production, like such as Hydroxyurea hydroxyurea (HU), as evidenced by an increased in HbF levels, have been considered as therapeutic agents for patients with β-thalassemiaTI. Increasing the synthesis of fetal hemoglobinHbF 1 can help reduce anemia and, thereby, improve the clinical condition of patients with β-TI. In several patients with β-TI and in patients with sickle-cell disease, a riseIncreases in total HbF levels has have been repeatedly reported during HU treatment in several patients with β-TI and in patients with sickle-cell disease. HU treatment can reduce blood transfusion dependency and even make some patients transfusion free, increasing which in turn increases their energy state level and decreasing decreases splenomegaly. HU treatment It also is protectiveprotects for against hypothyroidism, pulmonary hypertension, extramedullary hematopoiesis, leg ulcers, and osteoporosis. The commonest most common side effects of HU therapy treatment 2 include neutropenia and thrombocytopenia, ; both of which these are predictable and easily manageable. In the few studies conducted on the side effects of HU treatment in β-TI patients with β-TI, dermatological, neurological, and gastrointestinal adverse effects were seen observed without any reports of endocrine abnormality, bone marrow suppression, or hematological toxicity. In the present study, we aimed to perform medium- to long-term follow-up of chronic low-dose HU 3 treatment was inspected in order to analyze the its effect of HU treatment on the thyroid function of patients with β-TI.

Explanations

◂ サンプル一覧に戻る

アフターサービスをご利用したお客様の声

ジャーナルに受理・掲載された論文

Enago has helped hundreds of authors to get papers published. Below is a list of authors who have published their papers and who thank Enago in their paper for providing high-quality editing services.